TCGA-CN-A6UY-01A-12R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- E2F_TARGETS+0.360
- DNA_REPAIR+0.330
- ALLOGRAFT_REJECTION+0.280
- MYC_TARGETS_V1+0.230
- ADIPOGENESIS+0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
- SPERMATOGENESIS+0.170
- FATTY_ACID_METABOLISM+0.140
- INTERFERON_GAMMA_RESPONSE+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- UV_RESPONSE_DN-0.450
- HEDGEHOG_SIGNALING-0.440
- PROTEIN_SECRETION-0.410
- TGF_BETA_SIGNALING-0.400
- ANGIOGENESIS-0.350
- HYPOXIA-0.300
- KRAS_SIGNALING_UP-0.300
- ESTROGEN_RESPONSE_EARLY-0.260
- MYOGENESIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-KU-A6H7-06A-21R-A31N-07 | — | — | 0.924 |
| 2 | TCGA-IQ-A61I-01A-11R-A30B-07 | — | — | 0.922 |
| 3 | TCGA-P3-A5Q5-01A-11R-A28V-07 | — | — | 0.873 |
| 4 | TCGA-P3-A6SW-01A-11R-A34R-07 | — | — | 0.842 |
| 5 | TCGA-GV-A6ZA-01A-12R-A33J-07 | — | — | 0.841 |
| 6 | MDT-AP-2288 | Med | Medulloblastoma | 0.834 |
| 7 | TCGA-KU-A6H7-01A-11R-A31N-07 | — | — | 0.825 |
| 8 | c85dbfa4-b894-4ccb-9b90-94bb2c47cfea | — | — | 0.822 |
| 9 | TCGA-UP-A6WW-01A-12R-A34R-07 | — | — | 0.819 |
| 10 | acf70af7-cea9-4620-82c1-d488e7dab8d0 | — | — | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.020 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.020 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |